Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37970476)

  • 1. Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer.
    Razali NN; Raja Ali RA; Muhammad Nawawi KN; Yahaya A; Mohd Rathi ND; Mokhtar NM
    World J Gastroenterol; 2023 Oct; 29(40):5543-5556. PubMed ID: 37970476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Sequencing of Cytokine-Induced PI3K-Related Genes in Ulcerative Colitis, Colorectal Cancer and Colitis-Associated Cancer.
    Razali NN; Raja Ali RA; Muhammad Nawawi KN; Yahaya A; Mokhtar NM
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of microRNA-222-3p ameliorates ulcerative colitis and colitis-associated colorectal cancer to protect against oxidative stress
    Wang XJ; Zhang D; Yang YT; Li XY; Li HN; Zhang XP; Long JY; Lu YQ; Liu L; Yang G; Liu J; Hong J; Wu HG; Ma XP
    Front Immunol; 2023; 14():1089809. PubMed ID: 36776858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wumei Pill Ameliorates AOM/DSS-Induced Colitis-Associated Colon Cancer through Inhibition of Inflammation and Oxidative Stress by Regulating S-Adenosylhomocysteine Hydrolase- (AHCY-) Mediated Hedgehog Signaling in Mice.
    Wang J; Ding K; Wang Y; Yan T; Xu Y; Deng Z; Lin W; Zhang L; Zhu W; Zhao R; Zhou Y; Liu Z
    Oxid Med Cell Longev; 2022; 2022():4061713. PubMed ID: 35927991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice.
    Polytarchou C; Hommes DW; Palumbo T; Hatziapostolou M; Koutsioumpa M; Koukos G; van der Meulen-de Jong AE; Oikonomopoulos A; van Deen WK; Vorvis C; Serebrennikova OB; Birli E; Choi J; Chang L; Anton PA; Tsichlis PN; Pothoulakis C; Verspaget HW; Iliopoulos D
    Gastroenterology; 2015 Oct; 149(4):981-92.e11. PubMed ID: 26055138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis.
    Lee G; Goretsky T; Managlia E; Dirisina R; Singh AP; Brown JB; May R; Yang GY; Ragheb JW; Evers BM; Weber CR; Turner JR; He XC; Katzman RB; Li L; Barrett TA
    Gastroenterology; 2010 Sep; 139(3):869-81, 881.e1-9. PubMed ID: 20580720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a microRNA landscape targeting the PI3K/Akt signaling pathway in inflammation-induced colorectal carcinogenesis.
    Josse C; Bouznad N; Geurts P; Irrthum A; Huynh-Thu VA; Servais L; Hego A; Delvenne P; Bours V; Oury C
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(3):G229-43. PubMed ID: 24464560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxymatrine protects against DSS-induced colitis via inhibiting the PI3K/AKT signaling pathway.
    Chen Q; Duan X; Fan H; Xu M; Tang Q; Zhang L; Shou Z; Liu X; Zuo D; Yang J; Deng S; Dong Y; Wu H; Liu Y; Nan Z
    Int Immunopharmacol; 2017 Dec; 53():149-157. PubMed ID: 29107215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
    McPherson V; Reardon B; Bhayankara A; Scott SN; Boyd ME; Garcia-Grossman IR; Regazzi AM; McCoy AS; Kim PH; Al-Ahmadie H; Ostrovnaya I; Roth AJ; Farooki A; Berger MF; Rosenberg JE; Solit DB; Van Allen E; Milowsky MI; Bajorin DF; Iyer G
    Cancer; 2020 Oct; 126(20):4532-4544. PubMed ID: 32767682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.
    Estévez LG; García E; Hidalgo M
    Clin Transl Oncol; 2016 Jun; 18(6):541-9. PubMed ID: 26510854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive Effects of Polysaccharides and Flavonoids from Okra Flowers in Azomethane/Dextran Sulfate Sodium-Induced Murine Colitis-Associated Cancer.
    Deng Y; Huang X; Chen X; Wang M; Tian L; Zhou H; Yang W; He F; Yin W
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/AKT signaling is essential for communication between tissue-infiltrating mast cells, macrophages, and epithelial cells in colitis-induced cancer.
    Khan MW; Keshavarzian A; Gounaris E; Melson JE; Cheon EC; Blatner NR; Chen ZE; Tsai FN; Lee G; Ryu H; Barrett TA; Bentrem DJ; Beckhove P; Khazaie K
    Clin Cancer Res; 2013 May; 19(9):2342-54. PubMed ID: 23487439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
    Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
    J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
    Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
    Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora.
    Yan S; Chang J; Hao X; Liu J; Tan X; Geng Z; Wang Z
    Phytomedicine; 2022 Jul; 102():154217. PubMed ID: 35660350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    Anderson JL; Park A; Akiyama R; Tap WD; Denny CT; Federman N
    PLoS One; 2015; 10(9):e0133610. PubMed ID: 26402468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM21 Is Decreased in Colitis-associated Cancer and Negatively Regulates Epithelial Carcinogenesis.
    Zhou G; Wu H; Lin J; Lin R; Feng B; Liu Z
    Inflamm Bowel Dis; 2021 Mar; 27(4):458-468. PubMed ID: 32860065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/Akt signaling pathway is involved in the pathogenesis of ulcerative colitis.
    Huang XL; Xu J; Zhang XH; Qiu BY; Peng L; Zhang M; Gan HT
    Inflamm Res; 2011 Aug; 60(8):727-34. PubMed ID: 21442372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.